#Care1 #Mission-Cancer-01-03 # Pargmatic-clinical-trial #GustaveRoussy #QoL #new-biomarker #Cancercore #Horizon #Europe #Health-Economic #RIA #EUFunding&Tenders

NKI and VHIO Early Drug Development Know-How Exchange

Bianca Pont2023-09-20T13:24:49+02:00

NKI AND VHIO EARLY DRUG DEVELOPMENT KNOW-HOW EXCHANGE During September 14 and 15 2023, at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, Dr. Neeltje Steeghs and her team from the Netherlands Cancer Institute (NKI) met with Dr. Elena Garralda and her colleagues for know-how exchange sessions on early drug development. Both teams shared knowledge on a variety of related subjects for two days, including clinical research, clinical trial procedures, patient pathway interactions, and early drug development. Additionally, they had the chance to share information, progress, and upcoming plans for the CCE_DART and Basket of Baskets (BoB) trial projects, [...]

The CARE 1 Project is launched

2023-07-05T16:47:50+02:00

We are pleased to announce the launch of CARE1 Project, which officially started on May 1st, 2023. The project was submitted under the Call HORIZON-MISS-2022-CANCER-01-03, focused on pragmatic clinical trials to optimize treatments for patients with refractory cancers. CARE1 project is led by Gustave Roussy, with Prof. Laurence Albiges serving as the principal investigator. The European Commission has signed the Grant Agreement and approved the project on April 21st, with Grant N° 101104801. Over the next 60 months, CARE1 will be conducting a prospective randomized Phase III study, in a first-line setting for patients with metastatic clear cell RCC, comparing ICI-ICI [...]